TRASTUZUMAB VEDOTIN
UNII W95G28K44S

Substance Identification & Data

This profile provides standardized clinical and technical data for Trastuzumab Vedotin, uniquely identified by the FDA Unique Ingredient Identifier (UNII) W95G28K44S.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2740607-04-7 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

W95G28K44S

CAS Registry Number

2740607-04-7

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

TRASTUZUMAB VEDOTIN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C174205

National Cancer Institute reference terminology for clinical and research data.

INN ID

12531

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Trastuzumab Vedotin. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

TRASTUZUMAB VEDOTIN

Common Names & Synonyms

GAMMA1 HEAVY CHAIN HUMANIZED (1-450) (VH (HOMO SAPIENS IGHV3-66*01 (81.6%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT (8.8.13) (26-33.51-58.97-109)) (1-120) -HOMO SAPIENS IGHG1*03V, G1M3>G1M17, NG1M1 CH1 K120, CH3 E12, M14 (CH1 R120>K (217) (121-218), HINGE 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450))(121-450)), (223-214')-DISULFIDE WITH KAPPA LIGHT CHAIN HUMANIZED (1'-214') (V-KAPPA (HOMO SAPIENS IGKV1-39*01 (86.3%) - IGKJ1*01 (100%), CDR-IMGT (6.3.9) (27-32.50-52.89-97)) (1'-107') -HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (153), V101 (191) (108'-214')); DIMER (229-229'':232-232'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, CELL LINE CHO-DG44, GLYCOFORM ALFA; CONJUGATED, ON AN AVERAGE OF 3-4 CYSTEINYL, TO MONOMETHYLAURISTATIN E (MMAE), VIA A CLEAVABLE MALEIMIDOCAPROYL-VALYLCITRULLINYL-P-AMINOBENZYLOXYCARBONYL (MC-VAL-CIT-PABC) TYPE LINKER

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2, EPIDERMAL GROWTH FACTOR RECEPTOR 2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY; CONJUGATED TO AURISTATIN E

MRG 002 [WHO-DD]

TRASTUZUMAB VEDOTIN [INN]

TRASTUZUMAB--VCMMAE CONJUGATE